Abatacept plus + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myocarditis Acute
Conditions
Myocarditis Acute, Cancer
Trial Timeline
Jul 2, 2022 → Apr 20, 2027
NCT ID
NCT05335928About Abatacept plus + Placebo
Abatacept plus + Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Myocarditis Acute. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05335928. Target conditions include Myocarditis Acute, Cancer.
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05335928 | Phase 3 | Recruiting |
Competing Products
3 competing products in Myocarditis Acute
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SPIKEVAX | Moderna | Preclinical | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| Treatment with G-CSF (Granulocyte colony stimulating factor) + Placebo saline | Rafael Holdings | Phase 2 | 25 |